X4 Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Provided By GlobeNewswire
Last update: May 1, 2025
4WARD Phase 3 chronic neutropenia trial in full swing;
full enrollment on track for 3Q or 4Q 2025 and top-line data in 2H 2026
Additional analyses of mavorixafor clinical trial data increase confidence in successful outcome of 4WARD trial
Read more at globenewswire.comNASDAQ:XFOR (5/2/2025, 3:40:04 PM)
3.76
+0.01 (+0.27%)
Find more stocks in the Stock Screener
XFOR Latest News and Analysis
8 days ago - ChartmillStay updated with the stocks that are on the move in today's pre-market session.Before the opening bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
